[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncological-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncological-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100612823","the-tasty-training-study-100612823",false,"NCT07258589","The TASTY-training Study","Taste and Smell Training in Patients With Cancer Who Are Treated With Tyrosine Kinase Inhibitors: a Multicentre Randomized Intervention Trial","TASTY-training","Inclusion Criteria:\n\n* Age ≥18 and ≤70 years\n* Intention of being treated with tyrosine kinase inhibitors for next 12 weeks.\n* Experiencing taste alterations after starting treatment with tyrosine kinase inhibitors\n* Consuming solid foods and drinks is possible\n* ≤50% of recommended daily intake in kcal consisting of oral nutritional supplements\n* Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)\n* Ability to comply with all protocol-required actions\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* History of taste, smell, or saliva production dysfunction before treatment with tyrosine kinase inhibitors\n* Previous or current radiotherapy of head and neck region\n* Enteral feeding through tube or parenteral feeding\n* Participation in another clinical trial aimed at preventing or treating taste and\u002For smell alterations\n* Chronic (\\>1 month) high dose corticosteroids (\\>10 mg prednisone\u002Fday or equivalent)","ALL","18 Years","70 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","A multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste and smell training.\n\nTo examine the effect of at-home taste and smell training versus standard care on taste function and other outcome parameters, measurements will take place at baseline (before the training starts), and after 12 weeks. The intervention will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.",[28,29],"Oncological Patients","Tyrosine Kinase Inhibitor",[31],"Taste alterations","RECRUITING","2026-07-13",{"date":35,"type":36},"2026-07-15","ACTUAL",{"date":38,"type":36},"2025-11-10",{"date":40,"type":22},"2028-07",{"name":42,"class":43},"University Medical Center Groningen","OTHER",11,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100615663","analysis-of-the-specificity-and-persistence-of-nasal-immune-responses-to-respiratory-viral-antigens-in-immunocompromised-and-healthy-cohorts-100615663","NCT07295535","Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts","Inclusion Criteria:\n\n* Informed Consent: Participants must have signed an informed consent form.\n* Age Range: Participants aged between 18 and 90 years.\n* Healthy Immunocompetent Donors: no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications.\n* Immunocompromised Patients: subjects with medical conditions or treatments associated with significant impairment of the immune system. This may include organ or stem cell transplants, ongoing immunosuppressive therapies, documented genetic immunosuppression.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Individuals unable to provide informed consent","90 Years",{"count":53,"type":22},40,"OBSERVATIONAL","The goal of this observational study is to characterize nasal mucosal immunity to respiratory viruses, such as SARS-CoV-2, in immunocompromised individuals and healthy volunteers.\n\nThe study involves adults of any sex, between 18 and 90 years old, including both immunocompromised patients with medical conditions or treatments that can affect immune cell functions and healthy controls with no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications.\n\nResearchers will compare immunocompromised participants to healthy volunteers to determine how underlying immunodeficiency and related treatments affect immune cell composition and virus-specific responses.",[57,58,59,60,28],"Immuno-modulation","Immuno-suppression","Immunocompromised Patients","Healthy Subjects","2025-12-16",{"date":63,"type":36},"2025-12-19",{"date":65,"type":36},"2025-09-01",{"date":67,"type":22},"2027-09-30",{"name":69,"class":43},"Fondazione IRCCS Policlinico San Matteo di Pavia",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":54,"phases":4,"briefSummary":81,"conditions":82,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":70},"100569332","fertility-protection-for-children-adolescents-and-young-adults-100569332","NCT06692868","Fertility Protection for Children, Adolescents and Young Adults","FeProCAYA","Children, adolescents, young adults with a diagnosis of cancer before the age of 21 years\n\nor\n\nChildren, adolescents, young adults undergoing SCT for a malignant or non-malignant condition before the age of 21 years\n\ntreated at the Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.",{"count":79,"type":22},2000,"20 Years","This study focuses on improving fertility preservation and long-term care for children, adolescents, and young adults (CAYA) undergoing cancer treatments or stem cell transplantation. These treatments can harm fertility, and ensuring that patients receive the right support and follow-up care is critical.\n\nThe main study goals are:\n\n1. Understanding Fertility Risks: Researchers aim to identify factors that predict fertility problems after cancer treatments, such as the type of therapy, hormone levels, body composition, or genetic predispositions.\n2. Addressing Patient and Family Needs: The program will explore the concerns, needs, and challenges faced by young patients and their parents regarding fertility. It will also examine how these issues affect their quality of life.\n3. Improving Clinical Care: Current practices in fertility preservation and counseling will be studied to identify gaps and improve care structures.\n\nTo achieve these goals, the program will:\n\n* Create a database to collect and analyze medical data from patients before, during, and after cancer treatments.\n* Study the prevalence and long-term effects of fertility problems in young patients.\n* Document medical interventions like fertility preservation methods (e.g., freezing eggs or sperm) and treatments for late effects.\n* Assess patients' and families' fertility-related quality of life and their informational needs.\n\nUltimately, the project aims to establish an interdisciplinary center to support fertility preservation and improve the quality of care for young patients facing cancer and its treatments.",[83,84,85,28,86,87,88,89,90,91,92],"Stem Cell Transplant","Stem Cell Transplantation","Oncological Outcomes","Oncological Children","Fertility","Fertility Protection","Endocrinological Late-effects","Paediatric Oncology","CAYA","Survivors",[76,94,95,96,97,98,99,100,101,102,103,104,105,106,107,91],"Fertility protection","Endocrinological follow-up after oncological disease","children","fertility","adolescents","young adults","TYA","teenagers and young adults","paediatric oncology","follow-up care","endocrinological late-effects","survivors","stem cell transplant","stem cell transplantation","2025-01-13",{"date":110,"type":36},"2025-01-16",{"date":112,"type":36},"2024-12-09",{"date":114,"type":22},"2044-11",{"name":116,"class":43},"University of Ulm"]